Real-World Experience of Sustained-Release Fampridine in Chinese Patients With Multiple Sclerosis: A Case Series on Walking Impairment and Fatigue.
Аннотация
OBJECTIVES
To investigate the efficacy of sustained-release fampridine tablets (fampridine-SR) on walking impairment and fatigue on Chinese patients with multiple sclerosis (MS).
METHODS
All patients (n = 12) had the baseline Expanded Disability Status Scale (EDSS) at 4-7 and orally administered fampridine-SR at 10 mg twice per day for at least 12 weeks. All patients were assessed using EDSS, Timed 25-Foot Walk (T25FW), the 12-item Multiple Sclerosis Walking Scale (MSWS-12), and Modified Fatigue Impact Scale (MFIS) at baseline, day 1, week 1, 2, 4, 8, and 12.
RESULTS
The baseline EDSS score was 4.67 ± 0.36. Fampridine-SR significantly decreased the EDSS score by 0.63 ± 0.20 (p = 0.011) after 12-week treatment. T25FW was changed at day 1 and week 1 by - 12.73 ± 3.03% and - 14.20 ± 4.36% (p < 0.011), respectively. The statistically and clinically significant improvement of MSWS-12 was observed since week 1. The total, cognitive subscale, physical subscale, and psychosocial subscale of MFIS were significantly reduced in Chinese patients with MS.
CONCLUSION
Fampridine-SR was a fast-acting oral potassium channel blocker on improving walking ability of MS as early as day 1. It demonstrated the positive effects on walking impairment and fatigue, including the physical, cognitive, and psychosocial subscales of MFIS, in Chinese patients with MS.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.